## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# FORM 8-K

### **CURRENT REPORT**

## **PURSUANT TO SECTION 13 OR 15(d)** OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 20, 2019

# ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

0-17999

Massachusetts	0-17999	04-2726691
(State or other jurisdiction of	(Commission File Number)	(IRS Employer
incorporation)		Identification No.)
	Winter Street, Waltham, MA 0	
(Address	of principal executive offices) (	(Zip Code)
Registrant's telep	hone number, including area cod	le: (781) 895-0600
Check the appropriate box below if obligation of the registrant under any		d to simultaneously satisfy the filing General Instruction A.2. below):
☐ Written communications pu	ursuant to Rule 425 under the Sec	curities Act (17 CFR 230.425)
$\square$ Soliciting material pursuant	to Rule 14a-12 under the Excha	nge Act (17 CFR 240.14a-12)
$\square$ Pre-commencement commu 240.14d-2(b))	unications pursuant to Rule 14d-2	2(b) under the Exchange Act (17 CFR
	unications pursuant to Rule 13e-4	4(c) under the Exchange Act (17 CFR
240.13e-4(c))		
Securities registered pursuant to Se	ection 12(b) of the Act:	
		Name of Each Exchange on
Title of Each Class	Trading Symbol	Which Registered
Common Stock, \$.01 par	IMGN	NASDAQ Global Select
value		Market
•		h company as defined in Rule 405 of f the Securities Exchange Act of 1934
		Emerging growth company $\Box$
	ying with any new or revised fin	registrant has elected not to use the nancial accounting standards provided

#### ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At the 2019 annual meeting of shareholders of ImmunoGen, Inc. held on June 20, 2019 (the "2019 Annual Meeting"), shareholders fixed the number of Directors constituting the full Board of Directors at seven. The voting results were as follows:

For:	91,726,038
Against	1,797,920
Abstain	1,649,411
Broker Non-Votes	37,812,197

At the 2019 Annual Meeting, shareholders elected seven Directors as follows:

	<u>FOR</u>	<b>WITHHELD</b>	<b>BROKER NON-VOTES</b>
Stephen C. McCluski	92,114,710	3,058,659	37,812,197
Richard J. Wallace	91,883,648	3,289,721	37,812,197
Mark Goldberg, MD	68,875,778	26,297,591	37,812,197
Dean J. Mitchell	83,207,216	11,966,153	37,812,197
Kristine Peterson	53,851,530	41,321,839	37,812,197
Mark J. Enyedy Stuart A. Arbuckle	92,766,242 92,457,274	2,407,127 2,716,095	37,812,197 37,812,197

At the 2019 Annual Meeting, shareholders voted, on an advisory basis, against approval of the compensation paid to our named executive officers, as described in our proxy statement (the "say-on-pay vote") as follows:

For:	8,972,438
Against	84,438,717
Abstain	1,762,214
Broker Non-Votes	37,812,197

At the 2019 Annual Meeting, shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2020 as follows:

For:	129,553,210
Against	1,237,073
Abstain	2,195,283
Broker Non-Votes	0

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ImmunoGen, Inc.
(Registrant)

Date: June 24, 2019 /s/ Mark J. Enyedy

Mark J. Enyedy

President and Chief Executive Officer